Iovance Biotherapeutics Inc - Company Profile
Powered by
All the data and insights you need on Iovance Biotherapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Iovance Biotherapeutics Inc Strategy Report
- Understand Iovance Biotherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Iovance Biotherapeutics Inc (Iovance) is a biotechnology company that focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include lifileucel is an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer; and LN-145 for the treatment of head and neck cancer. The company also focuses on investigating TIL therapy for treatment of a various types of cancer. It has Iovance Cell Therapy Center (iCTC) in Philadelphia for the manufacture of the tumor infiltrating lymphocytes (TIL). The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
Iovance Biotherapeutics Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pipeline - | Proleukin8 |
Lifileucel – Melanoma, Cervical Cancer | |
LN-145/LN-145-S1- Head And Neck Cancer | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In February, the company received approval from the US Food and Drug Administration for AMTAGVI (lifileucel). |
2023 | Acquisitions/Mergers/Takeovers | In May, the company acquired entire shares of Clinigen SP Limited. |
2023 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration accepted its biologics license application for lifileucel for patients with advanced melanoma. |
Competitor Comparison
Key Parameters | Iovance Biotherapeutics Inc | Merck & Co Inc | AstraZeneca Plc | Bristol-Myers Squibb Co | Amgen Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United Kingdom | United States of America | United States of America |
City | San Carlos | Kenilworth | Cambridge | Princeton | Thousand Oaks |
State/Province | California | New Jersey | England | New Jersey | California |
No. of Employees | 557 | 72,000 | 89,900 | 34,100 | 26,700 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Iain Dukes, Ph.D. | Chairman | Executive Board | 2016 | 64 |
Frederick G. Vogt, Ph.D. | General Counsel; Interim Chief Executive Officer; Secretary | Executive Board | 2016 | 49 |
Jean-Marc Bellemin | Chief Financial Officer | Senior Management | 2020 | 51 |
Igor Bilinsky, Ph.D. | Chief Operating Officer | Senior Management | 2021 | 50 |
Friedrich Graf Finckenstein, M.D. | Chief Medical Officer | Senior Management | 2019 | 56 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer